Literature DB >> 12602501

Effects of hyperammonemia and liver failure on glutamatergic neurotransmission.

Pilar Monfort1, María-Dolores Muñoz, Amina ElAyadi, Elena Kosenko, Vicente Felipo.   

Abstract

Glutamate is the main excitatory neurotransmitter in mammals. Glutamatergic neurotransmission involves several steps, beginning with release of glutamate from the presynaptic neuron. Glutamate in the extracellular space activates glutamate receptors present in the synaptic membranes, leading to activation of signal transduction pathways associated with these receptors. To avoid continuous activation of glutamate receptors, glutamate is removed from the synaptic cleft by specific glutamate transporters located mainly on astrocytes. All these steps are tightly modulated under physiological conditions, and alterations of any of the above steps may result in impairment of glutamatergic neurotransmission, leading to neurological alterations. There are studies in the literature reporting alterations in all these steps in hyperammonemia and/or hepatic failure. Glutamatergic neurotransmission modulates important cerebral processes. Some of these processes are altered in patients with liver disease and hepatic encephalopathy, who show altered sleep-wake patterns, neuromuscular coordination, and decreased intellectual capacity. The alterations in glutamatergic neurotransmission may be responsible for some of these neurological alterations found in hepatic encephalopathy. The effects of hyperammonemia and liver failure on different steps of glutamatergic neurotransmission including alterations of glutamate concentration in the extracellular fluid in brain, transport and transporters of glutamate, the content and function of different types of glutamate receptors and signal transduction pathways. Alterations induced by hyperammonemia and liver failure on the glutamate-nitric oxide-cGMP pathway in brain may result in changes in long-term potetiation and learning ability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12602501     DOI: 10.1023/a:1021993431443

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  61 in total

1.  Hyperammonemia impairs NMDA receptor-dependent long-term potentiation in the CA1 of rat hippocampus in vitro.

Authors:  M D Muñoz; P Monfort; J M Gaztelu; V Felipo
Journal:  Neurochem Res       Date:  2000-04       Impact factor: 3.996

Review 2.  Glutamate and muscarinic receptors in the molecular mechanisms of acute ammonia toxicity and of its prevention.

Authors:  M D Miñana; M Llansola; C Hermenegildo; C Cucarella; C Montoliu; E Kosenko; S Grisolía; V Felipo
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

3.  Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure.

Authors:  C Rose; A Michalak; M Pannunzio; N Chatauret; A Rambaldi; R F Butterworth
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

4.  Changes in the extracellular profiles of neuroactive amino acids in the rat striatum at the asymptomatic stage of hepatic failure.

Authors:  W Hilgier; M Zielińska; H D Borkowska; R Gadamski; M Walski; S S Oja; P Saransaari; J Albrecht
Journal:  J Neurosci Res       Date:  1999-04-01       Impact factor: 4.164

5.  Reduction in the MK-801 binding sites of the NMDA sub-type of glutamate receptor in a mouse model of congenital hyperammonemia: prevention by acetyl-L-carnitine.

Authors:  K V Rao; I A Qureshi
Journal:  Neuropharmacology       Date:  1999-03       Impact factor: 5.250

Review 6.  N-acetylglutamate synthetase (NAGS) deficiency.

Authors:  J P Colombo
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

Review 7.  Evidence for an astrocytic glutamate transporter deficit in hepatic encephalopathy.

Authors:  H Chan; R F Butterworth
Journal:  Neurochem Res       Date:  1999-11       Impact factor: 3.996

8.  Effects of thioacetamide-induced hepatic failure on the N-methyl-D-aspartate receptor complex in the rat cerebral cortex, striatum, and hippocampus. Binding of different ligands and expression of receptor subunit mRNAs.

Authors:  P Saransaari; S S Oja; H D Borkowska; J Koistinaho; W Hilgier; J Albrecht
Journal:  Mol Chem Neuropathol       Date:  1997 Sep-Dec

9.  Flumazenil does not affect the increase in rat hippocampal extracellular glutamate concentration produced during thioacetamide-induced hepatic encephalopathy.

Authors:  P McArdle; D H Penning; F Dexter; J D Reynolds
Journal:  Metab Brain Dis       Date:  1996-12       Impact factor: 3.584

10.  Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure.

Authors:  A Michalak; C Rose; J Butterworth; R F Butterworth
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

View more
  23 in total

1.  Rabbit retinal organ culture as an in-vitro model of hepatic retinopathy.

Authors:  Heidrun Kuhrt; Michał Walski; Andreas Reichenbach; Jan Albrecht
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-02-18       Impact factor: 3.117

Review 2.  Contribution of altered signal transduction associated to glutamate receptors in brain to the neurological alterations of hepatic encephalopathy.

Authors:  Vicente Felipo
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

3.  Effects of cholestasis on learning and locomotor activity in bile duct ligated rats.

Authors:  Nasrin Hosseini; Hojjatallah Alaei; Mohammad Nasehi; Maryam Radahmadi; Zarrindast Mohammad Reza
Journal:  Malays J Med Sci       Date:  2014-01

4.  Chemical shift magnetic resonance spectroscopy of cingulate grey matter in patients with minimal hepatic encephalopathy.

Authors:  Sergei Mechtcheriakov; Michael Schocke; André Kugener; Ivo W Graziadei; Michael Mattedi; Hartmann Hinterhuber; Wolfgang Vogel; Josef Marksteiner
Journal:  Neuroradiology       Date:  2005-01-18       Impact factor: 2.804

5.  Neuroprotective effects of guanosine administration on behavioral, brain activity, neurochemical and redox parameters in a rat model of chronic hepatic encephalopathy.

Authors:  L G Paniz; M E Calcagnotto; P Pandolfo; D G Machado; G F Santos; G Hansel; R F Almeida; R S Bruch; L M Brum; F V Torres; A M de Assis; E P Rico; D O Souza
Journal:  Metab Brain Dis       Date:  2014-05-01       Impact factor: 3.584

Review 6.  Chronic hyperammonemia, glutamatergic neurotransmission and neurological alterations.

Authors:  Marta Llansola; Carmina Montoliu; Omar Cauli; Vicente Hernández-Rabaza; Ana Agustí; Andrea Cabrera-Pastor; Carla Giménez-Garzó; Alba González-Usano; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2012-09-26       Impact factor: 3.584

Review 7.  Cyclic GMP pathways in hepatic encephalopathy. Neurological and therapeutic implications.

Authors:  Carmina Montoliu; Regina Rodrigo; Pilar Monfort; Marta Llansola; Omar Cauli; Jordi Boix; Nisrin Elmlili; Ana Agusti; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2010-03-02       Impact factor: 3.584

Review 8.  Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy.

Authors:  Omar Cauli; Regina Rodrigo; Marta Llansola; Carmina Montoliu; Pilar Monfort; Blanca Piedrafita; Nisrin El Mlili; Jordi Boix; Ana Agustí; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2008-12-16       Impact factor: 3.584

9.  Acute Hyperammonemia Induces NMDA-Mediated Hypophosphorylation of Intermediate Filaments Through PP1 and PP2B in Cerebral Cortex of Young Rats.

Authors:  Rônan Vivian Carvalho; Fernanda da Silva Ferreira; Luana Heimfarth; Paula Pierozan; Carolina Fernandes; Regina Pessoa-Pureur
Journal:  Neurotox Res       Date:  2016-03-02       Impact factor: 3.911

10.  Whole Genome DNA Methylation Analysis of Obstructive Sleep Apnea: IL1R2, NPR2, AR, SP140 Methylation and Clinical Phenotype.

Authors:  Yung-Che Chen; Ting-Wen Chen; Mao-Chang Su; Chung-Jen Chen; Kuang-Den Chen; Chia-Wei Liou; Petrus Tang; Ting-Ya Wang; Jen-Chieh Chang; Chin-Chou Wang; Hsin-Ching Lin; Chien-Hung Chin; Kuo-Tung Huang; Meng-Chih Lin; Chang-Chun Hsiao
Journal:  Sleep       Date:  2016-04-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.